Twitter

Posts Tagged ‘nexavar’


India board rules against Bayer in cancer drug patent case

An Indian patent appeals board upheld on Monday a decision to allow a domestic company to sell a generic version of Bayer AG’s cancer drug Nexavar, in a blow for global drugmakers’ efforts to hold on to monopolies on high-price medicines.

Read More...

UPDATE 1-Bayer’s Nexavar meets goal in thyroid cancer trial

German drugmaker Bayer said its cancer treatment Nexavar reached a goal of improving the survival of patients with a certain type of thyroid cancer in a late-stage clinical trial.

Read More...

In Sloan-Kettering study, new drug shows promise for patients with advanced kidney cancer

People with advanced kidney cancer may have a new alternative in their limited arsenal of treatment options that are both well tolerated and effective against the disease. New research led by Memorial Sloan-Kettering has shown that the investigational drug tivozanib is more effective than an approved targeted therapy called sorafenib (Nexavar®) in delaying the growth of their cancer.

Read More...

Nexavar Dosing in Renal Cancer Patients in "Real-life" Setting

Condition :   Carcinoma, Renal Cell Intervention :   Drug: Sorafenib (Nexavar, BAY43-9006) Sponsor :   Bayer Recruiting – verified March 2012

Read More...

Nexavar® as First Targeted Therapy in Patients With Advanced Renal Cell Carcinoma

Condition :   Carcinoma, Renal Cell Intervention :   Drug: Sorafenib (Nexavar, BAY 43-9006) Sponsor :   Bayer Not yet recruiting – verified January 2012

Read More...

Sorafenib to Treat Children and Young Adults With Neurofibromatosis Type 1 and Inoperable Plexiform Neurofibromas

Conditions :   Neurofibromatosis Type I;   Plexiform Neurofibroma Interventions :   Drug: Nexavar (BAY 43-9006) (Sorafenib);   Drug: Toxicity, Pharmacokinetics;   Drug: Pharmacodynamics;   Drug: Radiographic Evaluation;   Drug: QOL assessment, Neuropsychological;   Drug: Bony Toxicity Sponsor :   National Cancer Institute (NCI) Completed – verified May 2011

Read More...

Orphan drug decisions: SMC 55 vs NICE 5

… RCC and hepatocellular cancer; and – Novartis’ Glivec (imatinib) for gastrointestinal stomal tumours and leukaemia. In three of the five instances – for Torisel and both indications for Nexavar …

Read More...

ONYX PHARMACEUTICALS INC – 10-Q – Management’s Discussion and Analysis of Financial Condition and Results of Operations

… that target the molecular mechanisms that cause cancer. Through our internal research programs and in … cancer, including lung, thyroid, breast, ovarian and colon cancers. We and Bayer are commercializing Nexavar, …

Read More...

Nexavar Post-marketing Surveillance for Renal Cell Carcinoma in Japan

Condition :   Carcinoma, Renal Cell Intervention :   Drug: Sorafenib (Nexavar, BAY43-9006) Sponsor :   Bayer Active, not recruiting – verified August 2011

Read More...

Nexavar Post-marketing Surveillance for Hepatocellular Carcinoma in Japan

Condition :   Carcinoma, Hepatocellular Intervention :   Drug: Sorafenib (Nexavar, BAY43-9006) Sponsor :   Bayer Recruiting – verified August 2011

Read More...